Gurney Austin, Senior Vice President at the Molecular and Cellular Division at Oncomed Pharmaceuticals Inc (NASDAQ:OMED) disclosed today the disposal of 4,000 shares of common stock on October 17, 2014, at a unit price of $20.07. This is Mr. Austin’s fifth sale this year for a total of 20,000 shares. He now directly owns 90,134 shares, including 20,000 restricted stock units.
John A. Lewicki, EVP and Chief Scientific Officer and Paul J. Hastings, Chairman and CEO at Oncomed Pharmaceuticals Inc (NASDAQ:OMED) have also disposed of shares this year. Mr. Lewicki and Mr. Hastings sold 164,546 and 67,600 shares each for unit prices ranging from $20.00 to $24.59, downsizing their holdings to 20,602 and 22,500 shares correspondingly.
Jerome Pfund And Michael Sjostrom’s Sectoral Asset Management is the largest shareholding institution (amongst those we track) now directly owning 1.4 million shares, for an estimated value of $32.5 million, after a reported 4% increment for the last filling period.
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.